NCT05819710View on ClinicalTrials.gov

A Study to Investigate the Next-day Residual Effects of TS-142 in Healthy Elderly Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

May 15, 2023

Primary Completion Date

August 25, 2023

Study Completion Date

August 25, 2023

Conditions
Healthy Subjects
Interventions
DRUG

TS-142

Single dose of 5 mg of TS-142

DRUG

TS-142

Single-dose of 10 mg of TS-142

DRUG

Zopiclone

Single-dose of 7.5 mg of zopiclone

DRUG

Placebo

Single-dose of placebo

Trial Locations (1)

Unknown

Taisho Pharmaceutical Co., Ltd selected site, Tokyo

All Listed Sponsors
lead

Taisho Pharmaceutical Co., Ltd.

INDUSTRY

NCT05819710 - A Study to Investigate the Next-day Residual Effects of TS-142 in Healthy Elderly Subjects | Biotech Hunter | Biotech Hunter